Celyad Oncology SA CLYYF
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 74.88M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.04
- Price/Sales
- 1,632.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4
- Website
- https://www.celyad.com
Valuation
|
Metric
|
CLYYF
|
|---|---|
Price/Earnings (Normalized) | 4.04 |
Price/Book Value | 8.74 |
Price/Sales | 1,632.86 |
Price/Cash Flow | — |
Price/Earnings
CLYYF
Financial Strength
|
Metric
|
CLYYF
|
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 0.94 |
Interest Coverage | 92.75 |
Quick Ratio
CLYYF
Profitability
|
Metric
|
CLYYF
|
|---|---|
Return on Assets (Normalized) | 18.19% |
Return on Equity (Normalized) | 378.55% |
Return on Invested Capital (Normalized) | 166.88% |
Return on Assets
CLYYF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^Q%!<$ | LOCK|%!jP | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f$Fhjs$ | LOCK|@>%! | $83B | |||
| Moderna Inc
MRNA
| LOCK|WRvzz!@ | LOCK|RJ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|#>b@Zwl | LOCK|HP | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$N!c>!R | LOCK|nG< | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X%J>M$n | LOCK|&%>@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|npr!%dbm | LOCK|@R!h? | $28B | |||
| Incyte Corp
INCY
| LOCK|?y?&yD$ | LOCK|ns | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#GvV&k^ | LOCK|#& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|fM#%Q> | LOCK|>f | $14B |
United States